2 results match your criteria: "The Stehlin Foundation for Cancer Research at Christus St. Joseph Hospital[Affiliation]"
Int J Oncol
January 2002
The Stehlin Foundation for Cancer Research at Christus St. Joseph Hospital, Houston, TX 77003, USA.
The purpose of this study is to establish the maximum tolerated dose of rubitecan in mice, dogs and men and to establish the anticancer activity of such dose against human tumors xenografted in nude mice. Nude mice received increasing doses of Rubitecan by intrastomach injection until the maximum tolerated dose (MTD) had been established for both the single dose and the multiple doses at the schedule of 5 days on, 2 days off. Extrapolating from the mouse data, MTD was determined for oral administration in dogs and man.
View Article and Find Full Text PDFHum Reprod Update
October 2001
Stehlin Foundation for Cancer Research at Christus St Joseph Hospital, Houston, Texas 77003, USA.
Oestrogens, including the natural hormones oestrone and oestradiol, induce various tumours in laboratory animals and have been recognized to be carcinogens in humans, raising the risk for breast and uterine cancer. As part of the search for the mechanism of hormone-induced carcinogenesis, various types of DNA damage have been detected which have been induced by oestrogens in cell-free systems, in cells in culture, or in vivo. Nevertheless, oestrogens have been postulated to act only as promoters of mammary carcinogenesis by receptor-mediated growth stimulation without consideration of their genotoxicity because these hormones failed to induce mutations in commonly used assays.
View Article and Find Full Text PDF